文献速递甲状腺疾病垂体与肾上腺疾病糖尿病

免疫检查点抑制剂相关的多发性或单一性内分泌异常

Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

基于日本DeSC医保行政数据库2014至2022年12978例接受免疫检查点抑制剂(ICI)治疗的患者,回顾性分析内分泌异常与总生存(OS)的关系。单一和多发性内分泌异常分别占12.0%和1.4%,最常见组合为甲状腺功能减退症合并肾上腺功能不全(1.3%)。多变量分析显示多发性(aHR 0.39;95%CI 0.28-0.54,P<.01)和单一性(aHR 0.65;95%CI 0.5-80.72,P<.01)内分泌异常患者死亡率均低于无内分泌异常者,且多发性异常者死亡率显著低于单一异常者(aHR 0.56;95%CI 0.39-0.79,P<.01)。

要点

  • ICI治疗患者中单一内分泌异常占12.0%,多发性占1.4%,最常见组合为甲状腺功能减退症合并肾上腺功能不全(1.3%)。
  • 多发性内分泌异常患者死亡率低于无内分泌异常者(aHR 0.39;95%CI 0.28-0.54,P<.01)。
  • 多发性内分泌异常患者死亡率显著低于单一内分泌异常者(aHR 0.56;95%CI 0.39-0.79,P<.01)。

核心结论

  • ICI治疗患者发生多发性内分泌异常与较单一内分泌异常者改善的生存相关。

研究设计与样本

  • 回顾性分析日本DeSC医保行政索赔数据库2014至2022年间接受ICI治疗的12978例患者。
  • 内分泌异常依据各激素替代治疗(左甲状腺素、氢化可的松、胰岛素)定义,难以区分中枢性或原发性激素缺陷;仅纳入甲状腺炎后甲状腺功能减退症患者;1型糖尿病另依据疾病名称和严格自我注射费用定义。
  • 采用回归分析识别内分泌异常的危险因素及其对OS的影响,校正包括ICI给药次数和持续时间在内的混杂因素。

主要发现

  • 单一和多发性内分泌异常分别见于12.0%和1.4%的患者。
  • 最常见的组合为甲状腺功能减退症合并肾上腺功能不全(1.3%)。
  • Kaplan-Meier分析显示多发性或单一性内分泌异常患者生存优于无内分泌异常者(P<.01)。
  • 多变量分析显示多发性内分泌异常患者死亡率低于无内分泌异常者(aHR 0.39;95%CI 0.28-0.54,P<.01)。
  • 多变量分析显示单一性内分泌异常患者死亡率低于无内分泌异常者(aHR 0.65;95%CI 0.5-80.72,P<.01),且多发性异常者死亡率显著低于单一异常者(aHR 0.56;95%CI 0.39-0.79,P<.01)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) are associated with various endocrine abnormalities. However, their underlying pathophysiology remains unclear. We investigated the effect of multiple endocrine abnormalities on the overall survival (OS) of patients treated with ICIs. METHODS: In total, 12 978 patients who received ICIs between 2014 and 2022 were investigated using the DeSC Japanese administrative claims database. Endocrine abnormalities were defined by each hormone replacement therapy, including levothyroxine, hydrocortisone, and insulin, in which it is difficult to distinguish central or primary hormone defect. Also, only patients with hypothyroidism after thyroiditis were included. Type 1 diabetes was additionally defined by the name of the disease and strict self-injection fees. Regression analyses were performed to identify risk factors for endocrine abnormalities and the effect of endocrine abnormalities on OS, adjusting for confounders including the number and duration of ICI administrations. RESULTS: Single and multiple endocrine abnormalities were observed in 12.0% and 1.4% of patients, respectively. The most common combination was hypothyroidism and adrenal insufficiency (1.3%). Kaplan-Meier analysis indicated better survival in patients with multiple and single endocrine abnormalities than in those without (P < .01). Multivariable analysis revealed lower mortality in patients with multiple and single endocrine abnormalities [adjusted hazard ratio (aHR) 0.39; 95% confidence interval (CI), 0.28-0.54, P < .01; aHR 0.65; 95% CI, 0.5-80.72, P < .01, respectively) than in those without. Mortality was significantly lower with multiple abnormalities than with single (aHR 0.56; 95% CI, 0.39-0.79, P < .01). CONCLUSION: The development of multiple endocrine abnormalities in patients treated with ICIs is associated with improved survival compared with that of patients with a single abnormality.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kamitani F, Nishioka Y, Nakajima H, et al. Multiple or Single Endocrine Abnormalities Associated With Immune Checkpoint Inhibitors. J Clin Endocrinol Metab. 2025. PMID: 40503677. doi:10.1210/clinem/dgaf347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。